Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.31 |
| ▸ | ANPEP | P15144 | 2/20 | 0.31 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.31 |
| ▸ | SCN1A | P35498 | 1/20 | 0.30 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.30 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21106835 | 0.97 | HRH4 (0.43) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL22861967 | 0.97 | HRH4 (0.43) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL9193203 | 0.97 | HRH4 (0.43) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL23806605 | 0.97 | HRH4 (0.43) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL11207707 | 0.97 | HRH4 (0.43) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL23695755 | 0.97 | HRH4 (0.43) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL22856504 | 0.97 | HRH4 (0.43) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL13879291 | 0.92 | LMNA (0.39) | LMNAHRH4HRH3ADH1BADH1C | |
| SCHEMBL9624660 | 0.89 | HRH4 (0.47) | HRH4HRH3ADH1BADH1CADH1A | |
| SCHEMBL21106926 | 0.87 | HRH4 (0.36) | LMNAHRH4HRH3SCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| EP-4194457-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-10428070-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190177320-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2019-05-23 | — | — | US | disclosed |
| US-9365599-B2 | N3S1 chelator-folate derivatives, preparation method thereof and composition for diagnosis or treatment of cancer containing the same as an active ingredient | KOREA ATOMIC ENERGY RESEARCH INSTITUTE (KR) | 2016-06-14 | — | — | US | disclosed |
| US-20130210887-A1 | DENDRIMERS AS NON-VIRAL VEHICLES FOR GENE THERAPY | UNIVERSIDAD DE CASTILLA LA MANCHA (ES) | 2013-08-15 | — | — | US | disclosed |
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | LMNA 2219/4885HRH4 4261/4885HRH3 4228/4885 |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885HRH4 3886/4885HRH3 3631/4885 |
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNB1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNY | LMNA 1304/4885HRH4 503/4885HRH3 832/4885 |
| US-20130210887-A1 | DENDRIMERS AS NON-VIRAL VEHICLES FOR GENE THERAPY | HAVCR2, GMFG, CD74 | LMNA 2611/4885HRH4 4341/4885HRH3 4372/4885 |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | LMNA 225/4885HRH4 3580/4885HRH3 3347/4885 |
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MYLK2, FKBP1B | LMNA 3053/4885HRH4 4739/4885HRH3 4818/4885 |
| US-20190177320-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | LMNA 2852/4885HRH4 2991/4885HRH3 3243/4885 |
| US-10428070-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | LMNA 2852/4885HRH4 2991/4885HRH3 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.